DE69434738D1 - Ein FAS Ligand, ein Fragment davon und kodierende DNA dafür - Google Patents

Ein FAS Ligand, ein Fragment davon und kodierende DNA dafür

Info

Publication number
DE69434738D1
DE69434738D1 DE69434738T DE69434738T DE69434738D1 DE 69434738 D1 DE69434738 D1 DE 69434738D1 DE 69434738 T DE69434738 T DE 69434738T DE 69434738 T DE69434738 T DE 69434738T DE 69434738 D1 DE69434738 D1 DE 69434738D1
Authority
DE
Germany
Prior art keywords
novel
novel polypeptide
dna
fragment
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69434738T
Other languages
English (en)
Other versions
DE69434738T2 (de
Inventor
Shigekazu Nagata
Takashi Suda
Tomohiro Takahashi
Norio Nakamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Osaka Bioscience Institute
Mochida Pharmaceutical Co Ltd
Original Assignee
Osaka Bioscience Institute
Mochida Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka Bioscience Institute, Mochida Pharmaceutical Co Ltd filed Critical Osaka Bioscience Institute
Application granted granted Critical
Publication of DE69434738D1 publication Critical patent/DE69434738D1/de
Publication of DE69434738T2 publication Critical patent/DE69434738T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69434738T 1993-11-10 1994-11-10 Ein FAS Ligand, ein Fragment davon und kodierende DNA dafür Expired - Lifetime DE69434738T2 (de)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
JP30597593 1993-11-10
JP30597593 1993-11-10
JP34252693 1993-12-13
JP34252693 1993-12-13
JP7434494 1994-03-18
JP7434494 1994-03-18
JP18095594 1994-07-08
JP18095594 1994-07-08
JP23936394 1994-09-07
JP23936394 1994-09-07
JP6278378A JPH08127594A (ja) 1993-11-10 1994-10-18 Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
JP27837894 1994-10-18

Publications (2)

Publication Number Publication Date
DE69434738D1 true DE69434738D1 (de) 2006-06-22
DE69434738T2 DE69434738T2 (de) 2006-11-16

Family

ID=27551293

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69434738T Expired - Lifetime DE69434738T2 (de) 1993-11-10 1994-11-10 Ein FAS Ligand, ein Fragment davon und kodierende DNA dafür

Country Status (9)

Country Link
US (1) US6348334B1 (de)
EP (1) EP0675200B1 (de)
JP (2) JPH08127594A (de)
KR (1) KR100384821B1 (de)
AT (1) ATE326535T1 (de)
AU (1) AU689157B2 (de)
CA (1) CA2153507C (de)
DE (1) DE69434738T2 (de)
WO (1) WO1995013293A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09508009A (ja) * 1994-01-07 1997-08-19 イミュネックス・コーポレーション Ｆａｓ抗原を結合するリガンド
US5759536A (en) * 1994-05-27 1998-06-02 University Technology Corporation Use of fas ligand to supress T-lymphocyte-mediated immune responses
US8715645B2 (en) 1994-05-27 2014-05-06 The Regents Of The University Of Colorado Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same
JP3451092B2 (ja) * 1995-03-20 2003-09-29 康 奥村 Ｆａｓリガンドに特異的に反応するモノクローナル抗体及びその製造方法
WO1996032935A1 (en) * 1995-04-21 1996-10-24 Ligand Pharmaceuticals Incorporated Inhibition of apoptosis in cells expressing fas-ligand following activation
US6114507A (en) * 1995-06-30 2000-09-05 Mochida Pharmaceutical Co., Ltd. Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
AU724856B2 (en) * 1995-06-30 2000-10-05 Mochida Pharmaceutical Co., Ltd. Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
US6096312A (en) * 1995-06-30 2000-08-01 Mochida Pharmaceutical Co., Ltd. Agent for suppressing a reduction of CD4+ lymphocytes
JPH09124509A (ja) * 1995-10-27 1997-05-13 Sumitomo Electric Ind Ltd 肝炎治療剤
DE19544332C2 (de) * 1995-11-28 1999-07-08 Deutsches Krebsforsch Verfahren zum Nachweis der Expression von CD95 Ligand in Zellen
DE19544333C2 (de) * 1995-11-28 1998-12-10 Deutsches Krebsforsch Verfahren zur Beurteilung der Aktivität von Arzneistoffen
DE69733773T2 (de) 1996-05-02 2006-04-20 Mochida Pharmaceutical Co. Ltd. Fas ANTIGEN-DERIVATE
US6027721A (en) * 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy
CA2260767A1 (en) 1996-07-19 1998-01-29 Takeda Chemical Industries, Ltd. Fas ligand-like protein, its production and use
US6777540B1 (en) 1996-09-02 2004-08-17 Ko Okumura Humanized immunoglobulin reacting specifically with Fas ligand or active fragments thereof and region inducing apoptosis originating in Fas ligand
DE19643093C2 (de) * 1996-10-18 1998-10-01 Apotech Sa Verwendung von FasL oder mit FasL transfizierten CD4·+·/FasL·-·/TH1-Zellinien oder von FasL in Kombination mit einem oder mehreren Cytokin(en) zur Bekämpfung von TH1/TH2-Krankheiten
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6001962A (en) * 1996-11-15 1999-12-14 The Regents Of The University Of California Modified Fas ligands
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US5858990A (en) * 1997-03-04 1999-01-12 St. Elizabeth's Medical Center Fas ligand compositions for treatment of proliferative disorders
EP1029550A4 (de) 1997-11-10 2001-09-26 Mochida Pharm Co Ltd Vorbeugende mittel und heilmittel gegen diffuse lungenkrankheiten
US6451759B1 (en) 1998-01-14 2002-09-17 The Regents Of The University Of California Noncleavable Fas ligand
ATE357931T1 (de) 1998-02-06 2007-04-15 Mochida Pharm Co Ltd Mittel zur prävention/behandlung entzündlicher darmerkrankungen
WO1999058150A1 (fr) * 1998-05-14 1999-11-18 Mochida Pharmaceutical Co., Ltd. Agents preventifs/remedes contre la cirrhose du foie
DE69932434D1 (de) * 1998-05-29 2006-08-31 Mochida Pharm Co Ltd Prophylaxe und Behandlung von autoimmunen Entmyelinisierungserkrankungen durch Fas-antagonisten
AU2880400A (en) * 1999-02-12 2000-08-29 Amgen, Inc. Tnf-related proteins
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US7879840B2 (en) * 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US7393652B2 (en) * 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
JP4734739B2 (ja) * 2000-09-29 2011-07-27 東レ株式会社 哺乳動物のガン抑制方法
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
DE60315815T2 (de) * 2002-03-21 2008-05-21 Eli Lilly And Co., Indianapolis ANTAGONISTISCHE HUMANE ANTI-hFAS-LIGAND-ANTIKÖRPER UND FRAGMENTE DAVON
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
JP2007525165A (ja) 2003-03-07 2007-09-06 トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク タイプ１ライアノジン受容体に基づく方法
WO2005012363A1 (ja) * 2003-08-01 2005-02-10 Mochida Pharmaceutical Co., Ltd. 標的化された炎症惹起剤
US8710045B2 (en) * 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
AU2007341631B9 (en) 2006-12-28 2012-10-04 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo
US20100050276A1 (en) * 2008-08-22 2010-02-25 Brown University Transgenic non-human animal models of apoptosis-mediated conditions
EP3076179A1 (de) 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnose und behandlung von minderwertigen glioma

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991010488A1 (en) * 1990-01-12 1991-07-25 Hal Levy Competitive dice and cube game
WO1991010448A1 (en) 1990-01-19 1991-07-25 German Cancer Research Center A cell surface antigen associated with cellular apoptosis
CA2067031C (en) 1991-04-26 2003-02-18 Shigekazu Nagata Dna coding for human cell surface antigen
JPH09508009A (ja) 1994-01-07 1997-08-19 イミュネックス・コーポレーション Ｆａｓ抗原を結合するリガンド

Also Published As

Publication number Publication date
JP3716936B2 (ja) 2005-11-16
KR100384821B1 (ko) 2003-08-27
CA2153507C (en) 2009-12-29
AU8115894A (en) 1995-05-29
WO1995013293A1 (fr) 1995-05-18
CA2153507A1 (en) 1995-05-18
JPH08127594A (ja) 1996-05-21
DE69434738T2 (de) 2006-11-16
ATE326535T1 (de) 2006-06-15
EP0675200B1 (de) 2006-05-17
EP0675200A1 (de) 1995-10-04
AU689157B2 (en) 1998-03-26
US6348334B1 (en) 2002-02-19

Similar Documents

Publication Publication Date Title
DE69434738D1 (de) Ein FAS Ligand, ein Fragment davon und kodierende DNA dafür
KR920000789A (ko) 면역글로불린 부분을 갖는 융합 단백질, 이의 제조방법 및 용도
ATE522610T1 (de) Menschliche, metabotrope glutamatrezeptor- subtypen (hmr6) und verwandte dns-verbindungen
DE60224291D1 (de) System zur antikörperexpression und- synthese
HUP0103758A2 (hu) Neurotróf faktorok
AU2768895A (en) Interleukin-1 beta converting enzyme like apoptosis protease-3 and 4
HK1011999A1 (en) Novel human beta2 integrin alpha subunit.
DE69630710D1 (de) Humaner tumornekrosefaktor delta und epsilon
BRPI0417959A (pt) anticorpo ou fragmento funcional deste, composição farmcêutica, método para tratamento ou profilaxia de acidente vascular cerebral e outras doenças/distúrbios neurológicos em um ser humano, uso de um anticorpo anti-nogo, e, métodos para inibir a neurodegeneração e/ou promover a recuperação funcional em um paciente humano, para promover o crescimento axonal, para produzir um anticorpo anti-nogo e para produzir uma composição farmacêutica intravenosamente administrável
IL124728A0 (en) Diagnosis and treatment of aur-1 and/or aur-2 related disorders
EA200200293A1 (ru) Бициклические аминокислоты в качестве фармацевтических агентов
DE69117949D1 (de) Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis
PT93345A (pt) Processo para a preparacao de moleculas de adn recombinante que codificam para receptores de interleuquina 2, de proteinas codificadas por este adn, de anticorpos monoclonais contra estas proteinas e de organismos hospedeiros transformados por este adn
WO2004053059A3 (en) Mitoneet polypeptide from mitochondrial membranes, modulators thereof, and methods of using the same
AU2820895A (en) Human chemokine beta-13
ATE271603T1 (de) Identifizierungsverfahren für substanzen die an das pyk2 polypeptid binden
EP0192175A3 (de) Polypeptide des Rhinovirusstammes HRV2 sowie die hierfür codierenden DNA-Moleküle
FI930626A0 (fi) Proteinstruktur hos vaexttoxingelonin
EP0261403A3 (de) Polypeptide des Rhinovirusstammes HRV89 sowie die hierfür codierenden DNA-Moleküle
DE69027967T2 (de) Proteine, die die expression von vertebraten-mhc-klasse-ii-genen regulieren, dafür kodierende dna-sequenzen und pharmazeutische zusammensetzungen
DE69521281D1 (de) Verfahren zur Herstellung von menschlichem oder humanem Matrilysin mittels rekombinanter DNA.
ATE304551T1 (de) Antivirales protein
ATE110112T1 (de) Verfahren und systeme zur herstellung von hiv- antigenen.
DE69127743T2 (de) Für ein Protein, das sich mit dem Enhancer des Alpha-Fetoprotein verbindet, kodierende DNS
WO2002010211A1 (fr) Nouveau polypeptide, proteine humaine a doigt de zinc 12.98, et polynucleotide codant ce polypeptide

Legal Events

Date Code Title Description
8364 No opposition during term of opposition